Pembrolizumab + MRGOO3 as Neoadjuvant in NPC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pembrolizumab + MRGOO3 as Neoadjuvant in NPC	nasopharyngeal carcinoma	Not yet recruiting	Phase 2	2025-12-05		NCT07267338

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Lepu Medical Technology (Beijing) Co., Ltd.	6
Merck Sharp & Dohme LLC	650
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	319

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Wuhan Xiehe Hospital	Wuhan	China	1

Clinical trials